01Approach to the Critical Patient/attcp48

Immediate priorities

›Critical recognition triggers

›Cyanosis disproportionate to clinical illness

›SpO2 persistently 70-85% despite supplemental oxygen

›PaO2 normal or elevated on ABG — excludes respiratory cause

›Failure to respond to 100% oxygen

›No improvement in SpO2 or clinical appearance with O2

›Distinguishes dyshemoglobinemia from pulmonary cyanosis

›Failure to respond to methylene blue

›Critical distinguishing feature from methemoglobinemia

›If methylene blue given empirically, non-response prompts SulfHb diagnosis

›Hemodynamic and airway assessment

›Airway patency and breathing effort

›Respiratory distress despite disproportionate cyanosis is a danger sign

›Intubation rarely required for isolated SulfHb but may be needed if hemolytic anemia severe

›Hemodynamic stability targets

›Heart rate and blood pressure assessment

›MAP > 65 mmHg as minimum perfusion target

›If syncope, AMS, or hemodynamic instability, immediate resuscitation bay

›Large bore IV access

›Cardiac monitoring

Key early actions

›Causative agent identification and cessation

›Immediate discontinuation of offending drug is the single most important intervention

›Phenazopyridine most common culprit

›Sulfonamides, dapsone, metoclopramide, phenacetin also implicated

›Methylene blue is NOT effective and should NOT be administered

›Worsening or no change after methylene blue confirms SulfHb over MetHb

02History/hx66

Medication exposure

›Causative drug exposure

›Phenazopyridine (most common)

›Available OTC for urinary analgesic use

›Onset often gradual over days to weeks of use

›Dapsone

›Used for dermatitis herpetiformis, leprosy, PCP prophylaxis

›Can cause both MetHb and SulfHb

›Sulfonamides including sulfamethoxazole

›Combination drugs increase exposure

›Metoclopramide particularly at high doses

›Case reports with concurrent N-acetylcysteine administration

›Phenacetin and acetanilid

›Older analgesics now less commonly available

›Flutamide and other oxidizing agents

Cyanosis characterization

›Onset and progression

›Gradual onset over days to weeks typical

›Distinguishes from acute methemoglobinemia onset

›Timing relative to drug initiation

›Duration of phenazopyridine use

›Dose and frequency of offending agent

›Associated symptoms

›Fatigue and exercise intolerance

›Dyspnea often milder than cyanosis severity suggests

›Near-syncope or syncope

›Headache and dizziness

03Physical Exam/exam47

Vitals and general appearance

›Vital sign pattern

›SpO2

›Characteristically 70-85% and non-responsive to supplemental O2

›SpO2 does not reflect true clinical status — patient often less ill than SpO2 implies

›Heart rate

›Often normal in mild cases

›Tachycardia indicates significant functional anemia or hemolysis

›Blood pressure

›Often preserved unless concurrent hemolysis and anemia severe

›Temperature

›Elevated if concurrent infection is H2S source

›General appearance

›Cyanosis disproportionate to degree of respiratory distress

›Patient appears more cyanotic than clinically ill — key diagnostic clue

›Color of cyanosis

›Bluish-gray or greenish hue

›May appear more pronounced than methemoglobinemia at equivalent dyshemoglobin levels

Skin and mucous membranes

›Cyanosis distribution

›Central cyanosis involving lips, tongue, and mucous membranes

›Distinguishes from peripheral cyanosis of poor perfusion

›Nail beds and perioral region involved

›Diffuse bluish-gray or greenish skin discoloration

›Greenish tint can be more prominent than in methemoglobinemia

›Blood color at venipuncture

›Characteristically dark greenish-brown

›Does not turn red with oxygen exposure

04Differential Diagnosis/ddx44

Life-threatening mimics

›Methemoglobinemia

›ICD-10 D74.0 congenital, D74.8 other

›Most important mimic — responds to methylene blue

›Co-oximetry directly measures MetHb — falsely elevated in SulfHb

›Cyanide addition test distinguishes the two

›Same drug culprits can cause both

›Dapsone, sulfonamides, phenazopyridine

›Carboxyhemoglobinemia

›ICD-10 T58 toxic effect of carbon monoxide

›Cherry-red skin coloration

›CO exposure history — house fire, generator, vehicle exhaust

›Elevated COHb on co-oximetry

›Cyanotic congenital heart disease

›ICD-10 Q24.9

›Abnormal echocardiogram

›History since birth

›Clubbing in chronic cases

›Intracardiac shunt with right-to-left flow

›PaO2 will be low (unlike SulfHb where PaO2 is normal)

Pulmonary causes of cyanosis

›Severe pneumonia or ARDS

›ICD-10 J18.9 pneumonia, J80 ARDS

›Abnormal PaO2 — key distinguishing feature from SulfHb

›Bilateral infiltrates on imaging

›Clinical illness severity matches cyanosis severity

›Massive pulmonary embolism

›ICD-10 I26.01 with acute cor pulmonale

05Laboratory Tests/lt53

Co-oximetry and blood gas

›Arterial blood gas with co-oximetry

›PaO2 normal or elevated — key diagnostic feature

›Excludes primary pulmonary cause of cyanosis

›Dissolved oxygen delivery marginally supported by supplemental O2

›Standard co-oximetry interpretation limitation

›SulfHb absorbs at approximately 620 nm — same wavelength as MetHb

›Standard 4-wavelength co-oximeter cannot distinguish SulfHb from MetHb

›Falsely reports elevated MetHb — called pseudomethemoglobinemia

›Expanded wavelength co-oximetry

›Newer instruments with additional wavelengths can quantify SulfHb directly

›Wu and Kenny (Clinical Chemistry 1997) described OSM3 co-oximeter measurement

Confirmatory testing

›Spectrophotometry with cyanide addition (Evelyn-Malloy method)

›Gold standard for diagnosis

›Cyanide converts MetHb to cyanmethemoglobin eliminating 620 nm peak

›SulfHb peak at 620 nm persists after cyanide addition

›Differentiates SulfHb from MetHb definitively

›Requires specialized laboratory analysis

›Not available at point of care

›Contact hematology or toxicology for coordination

›HPLC analysis

›High-performance liquid chromatography can identify and quantify SulfHb

›Used in complex cases or when spectrophotometry unavailable

›Harangi et al. (Clinical Toxicology 2007) described post-polypectomy case

›Bedside methylene blue challenge

›Failure to improve cyanosis after methylene blue is a practical bedside clue

›1-2 mg/kg IV methylene blue typical MetHb dose

06Diagnostic Tests/dt50

Scoring Systems

›Severity assessment framework

›SulfHb level as functional anemia marker

›Cyanosis visible at SulfHb as low as 0.5 g/dL (vs 1.5 g/dL for MetHb)

›Moderate severity approximately 10-20% of total hemoglobin affected

›Severe cases with high SulfHb fraction and symptomatic anemia

›Clinical severity classification

›Mild: cyanosis without symptoms, hemodynamically stable

›Moderate: dyspnea on exertion, fatigue, presyncope

›Severe: syncope, altered mental status, hemodynamic instability, concurrent hemolysis

›No validated scoring tool specific to sulfhemoglobinemia

›Clinical assessment and SulfHb fraction guide management

›Baseline cardiopulmonary reserve influences severity at equivalent SulfHb levels

MRI

›MRI role in sulfhemoglobinemia

›No primary diagnostic role for MRI in sulfhemoglobinemia

›Imaging is used to exclude alternative diagnoses

›MRI brain if neurologic symptoms suggest cerebral hypoxia sequelae

›MRI cardiac if echocardiography inconclusive for structural cause

›Intracardiac shunt characterization

›Complex congenital anatomy

›Contraindications to MRI

›Hemodynamically unstable patient

›Metallic implants incompatible with magnetic field

CT

›CT chest indications

›Exclude pulmonary cause of cyanosis when PaO2 abnormal

›Pulmonary embolism with CTPA

07Disposition/dispo41

Admission indications

›Criteria for hospital admission

›Symptomatic sulfhemoglobinemia

›Syncope or presyncope

›Dyspnea at rest

›Altered mental status

›Concurrent hemolytic anemia

›Hemoglobin below transfusion threshold

›Active hemolysis with falling hemoglobin

›Need for transfusion or exchange transfusion

›Symptomatic anemia despite drug cessation

›Life-threatening SulfHb fraction

›Neonatal or pediatric cases

›Lower threshold for admission due to limited reserve

›Diagnostic uncertainty requiring monitoring

›Inability to confirm SulfHb vs MetHb at bedside

ICU indications

›Criteria for intensive care

›Hemodynamic instability

›Hypotension requiring vasopressor support

›Suspected cardiac output impairment

›Severe functional anemia requiring exchange transfusion

›Continuous monitoring during exchange procedure

›Hematology and transfusion medicine co-management

›Concurrent sepsis from H2S-producing organism

›Vasopressor requirement

›Multi-organ dysfunction

08Treatment/t61

Immediate management

›Drug cessation as primary intervention

›Identify and immediately discontinue the offending agent

›Phenazopyridine cessation

›Dapsone, sulfonamide, or metoclopramide cessation as applicable

›Ensure medication is removed from active prescription list

›Patient counseling on permanent avoidance

›Document in allergy and problem list

›Inform patient that cyanosis will slowly resolve over weeks to months

›Supplemental oxygen

›Supplemental O2 despite SpO2 not responding

›Marginally improves dissolved oxygen delivery

›Does not appreciably change SpO2 or cyanosis appearance

›Reasonable supportive measure for symptomatic patients

Agents to avoid

›Methylene blue contraindicated in sulfhemoglobinemia

›Mechanism of action requires NADPH-dependent reduction — converts MetHb to Hb

›Sulfhemoglobin is irreversible and not reduced by methylene blue

›Administration will not improve cyanosis

›If given empirically for presumed MetHb and fails, consider SulfHb

›Non-response is a diagnostic clue

›Standard dose 1-2 mg/kg IV over 5 minutes

›Ascorbic acid similarly ineffective for SulfHb

›Ascorbic acid reduces MetHb but not SulfHb

Transfusion strategy

›Simple red blood cell transfusion

›Indication: symptomatic anemia or hemolysis with hemoglobin below safe threshold

›Target hemoglobin based on clinical symptoms rather than absolute number

›Type and crossmatch on admission if transfusion anticipated

›Replaces normal RBCs to improve oxygen-carrying capacity

›Dilutes SulfHb fraction as affected RBCs are cleared over 120 days

›Does not remove sulfhemoglobin from existing RBCs

›Exchange transfusion

›Indication: severe life-threatening sulfhemoglobinemia

›High SulfHb fraction causing significant functional anemia

›Hemodynamic compromise or altered mental status from hypoxia

›Rapidly reduces SulfHb fraction by replacing affected RBCs

›Most effective intervention when pharmacologic reversal unavailable

›Hematology and transfusion medicine coordination required

›Neonatal exchange transfusion

›Established therapy for neonatal SulfHb with hemolytic anemia

›Murphy et al. (Pediatrics 2015) — neonatal Morganella morganii-associated case

Treatment of underlying cause

›Infection-related H2S production

›Appropriate antibiotics for causative organism

›UTI with H2S-producing organisms: targeted antibiotic therapy

›E. coli UTI: trimethoprim-sulfamethoxazole (note: sulfas can worsen SulfHb — prefer alternative)

›Nitrofurantoin or fluoroquinolone for uncomplicated UTI if no SulfHb-inducing concern

›Morganella morganii: third-generation cephalosporin or fluoroquinolone

›Bowel management for constipation-related H2S production

›Osmotic laxatives or stool softeners to normalize bowel habits

›High-fiber diet and adequate hydration

Monitoring during recovery

›Serial laboratory monitoring

›Complete blood count every 24-48 hours if hemolysis present

›Monitor hemoglobin trend

›Reticulocyte count for hemolysis resolution

›Hemolysis markers until normalized

›LDH, haptoglobin, unconjugated bilirubin

›Repeat co-oximetry or spectrophotometry as available

›SulfHb fraction trend over time

›Clinical recovery timeline

›Cyanosis gradually resolves over weeks to months

›Natural RBC lifespan approximately 120 days

›Affected RBCs cleared as normal RBCs produced

›SpO2 will not normalize until clearance complete

09Special Populations/sp61

Pregnancy

›Physiologic considerations in pregnancy

›Increased oxygen demand of pregnancy

›Fetal hemoglobin (HbF) has higher O2 affinity — fetus partially protected

›Maternal SulfHb reduces oxygen delivery to placenta

›Fetal monitoring required when viable gestation affected

›Physiologic anemia of pregnancy

›Baseline lower hemoglobin increases vulnerability to functional anemia from SulfHb

›Lower threshold for transfusion in third trimester

›Drug safety in pregnancy

›Phenazopyridine — Category B but data limited

›Discontinue immediately if SulfHb confirmed

›Avoid prolonged use in pregnancy

›Dapsone — Category C

›Risk-benefit discussion with obstetrics

›Neonatal hemolysis risk if used near delivery

›Sulfonamides — avoid near term

›Risk of neonatal jaundice due to bilirubin displacement

›Imaging considerations

›Chest X-ray with abdominal shielding if clinically indicated

›Do not withhold CXR when diagnosis requires it

›CT with fetal dose minimization protocols when necessary

›MRI preferred over CT when time permits

Geriatric

›Phenazopyridine in older adults

›OTC availability creates frequent exposure in older patients with recurrent UTI

›Morales et al. (J Emerg Med 2021) — case in 83-year-old presenting with dyspnea

›Multiple comorbidities reduce tolerance for functional anemia

10Background/b69

Epidemiology

›Incidence and population patterns

›Rare condition with limited population-level data

›Exact incidence unknown — underdiagnosed due to diagnostic challenges

›Case reports and small series dominate literature

›Drug-induced cases most common in developed countries

›Phenazopyridine as leading cause in North America

›OTC availability contributes to unmonitored use

›Occupational cases from H2S exposure

›Petroleum refining, sewage treatment, mining sectors

›Agricultural settings with manure pits and biogas production

›Demographics

›Older adults more frequently exposed to phenazopyridine for recurrent UTI

›Women more commonly affected due to recurrent UTI rates

›Neonatal cases represent distinct high-risk group

›H2S-producing gut pathogens in immunologically naive neonates

›Pediatric cases associated with immunocompromising conditions

›Dapsone use in HIV-positive children, spina bifida with recurrent catheter UTIs

Pathophysiology

›Molecular mechanism of sulfhemoglobin formation

›Sulfur atom incorporation into porphyrin ring of hemoglobin

›Irreversible modification — cannot be enzymatically reduced

›Sulfhemoglobin does not carry oxygen at the sulfated heme iron site

›Sulfur sources

›Hydrogen sulfide (H2S) from drug metabolism or gut bacterial production

›Oxidizing drugs provide the oxidative environment enabling H2S-heme reaction

›Oxygen transport impairment

›Functional anemia mechanism

›Each sulfated heme unit removed from O2-carrying capacity

›Unlike MetHb, SulfHb causes rightward shift of dissociation curve in remaining Hb

›Rightward shift enhances O2 unloading — explains better clinical tolerance vs MetHb

›Threshold for visible cyanosis

›SulfHb 0.5 g/dL produces visible cyanosis (vs 1.5 g/dL MetHb, 5 g/dL deoxyHb)

›Patient appears profoundly cyanotic with relatively modest functional impairment

›Irreversibility

›No enzymatic reduction pathway exists

›Methemoglobin reductase is inactive against SulfHb

›Methylene blue and ascorbic acid — ineffective

›Resolution only by RBC senescence

›Normal RBC lifespan approximately 120 days

›Cyanosis resolves over weeks to months as affected cells cleared

›Spectral absorption

›SulfHb absorbs light at approximately 620 nm

›Same wavelength as MetHb — causes co-oximeter misclassification

›Pseudomethemoglobinemia on standard 4-wavelength co-oximetry

›Cyanide addition eliminates MetHb peak but not SulfHb peak — diagnostic

Therapeutic Considerations

›Evidence base and treatment philosophy

›No pharmacologic antidote exists

›Unlike methemoglobinemia, no reducing agent reverses SulfHb

›Drug cessation and supportive care are the cornerstones of treatment

›Expectant management for mild disease

›Spontaneous resolution over 120 days as RBCs turn over

›Patient education reduces anxiety about persistent cyanosis

›Transfusion decision-making

›Simple transfusion for symptomatic anemia

›Effective at increasing functional hemoglobin mass

›Dilutes SulfHb fraction

›Exchange transfusion reserved for severe or life-threatening cases

›Rapidly normalizes SulfHb fraction

›Risk of citrate toxicity and transfusion reactions

›Institutional expertise required

›Prevention strategy

›Medication review in recurrent UTI patients before prescribing phenazopyridine

›Limit duration to 2 days maximum for symptom relief

›Ensure renal function adequate for drug clearance

›Occupational H2S exposure mitigation

›Personal protective equipment in high-risk workplaces

›Atmospheric monitoring for H2S levels

›Bowel regimen for chronic constipation

›Prevents endogenous H2S accumulation

›Daily laxative in constipated patients on oxidizing drugs

11Patient Discharge Instructions/pdi34

copy discharge instructions

›Sulfhemoglobinemia home care instructions

›Your blue or grey skin color is caused by a change in your blood from a medication or chemical

›The medication has been stopped

›Your color will slowly return to normal over several weeks to months as your body makes new blood cells

›You do not need to take any special medication at home to reverse this

›No antidote or reversal agent exists

›The process reverses on its own

›Medications to permanently avoid

›You must never take the following medications again

›Phenazopyridine (Pyridium, AZO) — urinary pain reliever available over the counter

›Any medication identified as the cause of your episode

›Tell all your doctors and pharmacists about this reaction

›It should be listed in your medical records as a drug reaction

›Activity and diet at home

›Rest as needed if you feel short of breath or tired

›Limit strenuous activity until color improves and symptoms resolve

›Drink plenty of fluids and eat high-fiber foods

›Prevent constipation to reduce sulfur buildup in the gut

›No special diet required beyond normal healthy eating

›Warning signs — return to the emergency department immediately

›Sudden difficulty breathing at rest

›Unable to speak full sentences

›Fainting or loss of consciousness

›Chest pain

›Confusion or unusual sleepiness

›Worsening color (more blue or grey than at discharge)

›Rapid heart rate or palpitations at rest

12References/r29

Guidelines and key sources

›Landmark case series and reviews

›Lu HC, Shih RD, Marcus S, Ruck B, Jennis T. Pseudomethemoglobinemia: A Case Report and Review of Sulfhemoglobinemia. Archives of Pediatrics and Adolescent Medicine. 1998

›Key reference: co-oximetry misclassification, cyanide addition test, clinical review

›Morales A, Walsh R, Brown W, Checinski P, Williams SR. Case Report: Phenazopyridine-Induced Sulfhemoglobinemia in an 83-Year-Old Presenting With Dyspnea. Journal of Emergency Medicine. 2021

›Typical geriatric presentation with OTC phenazopyridine

›Gopalachar AS, Bowie VL, Bharadwaj P. Phenazopyridine-Induced Sulfhemoglobinemia. Annals of Pharmacotherapy. 2005

›Drug mechanism and clinical course

›Specialized diagnostic references

›Stepanenko T, Zajac G, Czajkowski A, et al. Sulfhemoglobin Under the Spotlight. Biochimica et Biophysica Acta. 2023

›Molecular characterization, Raman spectroscopy, detection methods

›Wu C, Kenny MA. A Case of Sulfhemoglobinemia and Emergency Measurement With OSM3 CO-oximeter. Clinical Chemistry. 1997

›Expanded wavelength co-oximetry for direct SulfHb measurement

›Askew SW, Baranoski GVG. Dysfunctional Hemoglobins and Cyanosis Connection. Biomedical Optics Express. 2018

›Optical differentiation of SulfHb and MetHb

›Pediatric and neonatal references

›Murphy K, Ryan C, Dempsey EM, et al. Neonatal Sulfhemoglobinemia and Hemolytic Anemia Associated With Intestinal Morganella Morganii. Pediatrics. 2015

›Neonatal case with exchange transfusion

›Campagna G, Espaillat A, Pfeiffer T, et al. Sulfhemoglobinemia Secondary to a Urinary Tract Infection. Journal of Pediatric Hematology/Oncology. 2020

›Pediatric UTI-associated case

›Langford JS, Sheikh S. Sulfhemoglobinemia Associated With High-Dose Metoclopramide and N-Acetylcysteine. Annals of Emergency Medicine. 1999

›Adolescent case with combined drug exposure

ICD-10 and coding

›Diagnostic coding references

›ICD-10 D74.8 — other methemoglobinemias (used for acquired sulfhemoglobinemia in many coding systems)

›No distinct ICD-10 code exists for sulfhemoglobinemia in ICD-10-CM

›SNOMED CT concept: sulfhemoglobinemia disorder

›ICD-10 T39.1 — poisoning by phenazopyridine if drug-induced context

Evidence & Review

Evidence & Review